187 related articles for article (PubMed ID: 38260136)
21. New PET Radiotracers for the Imaging of Neuroendocrine Neoplasms.
Fortunati E; Argalia G; Zanoni L; Fanti S; Ambrosini V
Curr Treat Options Oncol; 2022 May; 23(5):703-720. PubMed ID: 35325412
[TBL] [Abstract][Full Text] [Related]
22. Surgery in Patients with Gastro-Entero-Pancreatic Neuroendocrine Carcinomas, Neuroendocrine Tumors G3 and High Grade Mixed Neuroendocrine-Non-Neuroendocrine Neoplasms.
Holmager P; Langer SW; Kjaer A; Ringholm L; Garbyal RS; Pommergaard HC; Hansen CP; Federspiel B; Andreassen M; Knigge U
Curr Treat Options Oncol; 2022 Jun; 23(6):806-817. PubMed ID: 35362798
[TBL] [Abstract][Full Text] [Related]
23. A Consensus-Developed Morphological Re-Evaluation of 196 High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms and Its Clinical Correlations.
Elvebakken H; Perren A; Scoazec JY; Tang LH; Federspiel B; Klimstra DS; Vestermark LW; Ali AS; Zlobec I; Myklebust TÅ; Hjortland GO; Langer SW; Gronbaek H; Knigge U; Tiensuu Janson E; Sorbye H
Neuroendocrinology; 2021; 111(9):883-894. PubMed ID: 33002892
[TBL] [Abstract][Full Text] [Related]
24. A retrospective review of diagnosis and treatment modalities of neuroendocrine tumors (excluding primary lung cancer) in 10 oncological institutions of the East German Study Group of Hematology and Oncology (OSHO), 2010-2012.
Maschmeyer G; Mügge LO; Kämpfe D; Kreibich U; Wilhelm S; Aßmann M; Schwarz M; Kahl C; Köhler S; Grobe N; Niederwieser D
J Cancer Res Clin Oncol; 2015 Sep; 141(9):1639-44. PubMed ID: 25773126
[TBL] [Abstract][Full Text] [Related]
25. Peptide receptor radionuclide therapy (PRRT) in metastatic neuroendocrine tumors of unknown primary (CUP-NETs).
Baum RP; Wang P; Jakobsson V; Zhao T; Schuchardt C; Khong PL; Zhang J
Theranostics; 2024; 14(1):133-142. PubMed ID: 38164147
[No Abstract] [Full Text] [Related]
26. [Analysis of clinicopathological characteristics, therapeutic strategy and prognosis of 501 patients with gastric neuroendocrine neoplasms attending a single center].
Zhang BL; Lu YX; Liang WQ; Gao YH; Xi HQ; Wang XX; Zhang KC; Chen L
Zhonghua Wei Chang Wai Ke Za Zhi; 2023 May; 26(5):459-466. PubMed ID: 37217354
[No Abstract] [Full Text] [Related]
27. Correlation and Comparison of Somatostatin Receptor Type 2 Immunohistochemical Scoring Systems with 68Ga-DOTATATE Positron Emission Tomography/Computed Tomography Imaging in Gastroenteropancreatic Neuroendocrine Neoplasms.
Yu J; Cao F; Zhao X; Xie Q; Lu M; Li J; Yang Z; Sun Y
Neuroendocrinology; 2022; 112(4):358-369. PubMed ID: 34077939
[TBL] [Abstract][Full Text] [Related]
28. Comparison of the Impact of 68Ga-DOTATATE and 18F-FDG PET/CT on Clinical Management in Patients with Neuroendocrine Tumors.
Panagiotidis E; Alshammari A; Michopoulou S; Skoura E; Naik K; Maragkoudakis E; Mohmaduvesh M; Al-Harbi M; Belda M; Caplin ME; Toumpanakis C; Bomanji J
J Nucl Med; 2017 Jan; 58(1):91-96. PubMed ID: 27516446
[TBL] [Abstract][Full Text] [Related]
29. Management of Well-Differentiated High-Grade (G3) Neuroendocrine Tumors.
Sonbol MB; Halfdanarson TR
Curr Treat Options Oncol; 2019 Aug; 20(9):74. PubMed ID: 31428952
[TBL] [Abstract][Full Text] [Related]
30. [Clinicopathologic features and prognostic analysis of 240 patients with gastric neuroendocrine neoplasms].
Liang WQ; Zhang W; Qiao S; Wang BH; Wang C; Zhuang ZW; Xi HQ; Cai AZ; Wei B; Chen L
Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Jan; 23(1):38-43. PubMed ID: 31958929
[No Abstract] [Full Text] [Related]
31. Diagnostic Management of Gastroenteropancreatic Neuroendocrine Neoplasms: Technique Optimization and Tips and Tricks for Radiologists.
Pellegrino F; Granata V; Fusco R; Grassi F; Tafuto S; Perrucci L; Tralli G; Scaglione M
Tomography; 2023 Jan; 9(1):217-246. PubMed ID: 36828370
[TBL] [Abstract][Full Text] [Related]
32. An analysis of 130 neuroendocrine tumors G3 regarding prevalence, origin, metastasis, and diagnostic features.
Kasajima A; Konukiewitz B; Schlitter AM; Weichert W; Klöppel G
Virchows Arch; 2022 Feb; 480(2):359-368. PubMed ID: 34499237
[TBL] [Abstract][Full Text] [Related]
33. Correlation of somatostatin receptor PET/CT imaging features and immunohistochemistry in neuroendocrine tumors of the lung: a retrospective observational study.
Rufini V; Lorusso M; Inzani F; Pasciuto T; Triumbari EKA; Grillo LR; Locco F; Margaritora S; Pescarmona E; Rindi G
Eur J Nucl Med Mol Imaging; 2022 Oct; 49(12):4182-4193. PubMed ID: 35674739
[TBL] [Abstract][Full Text] [Related]
34. Expression of Somatostatin Receptor (SSTR) Subtypes (SSTR-1, 2A, 3, 4 and 5) in Neuroendocrine Tumors Using Real-time RT-PCR Method and Immunohistochemistry.
Mizutani G; Nakanishi Y; Watanabe N; Honma T; Obana Y; Seki T; Ohni S; Nemoto N
Acta Histochem Cytochem; 2012 Jun; 45(3):167-76. PubMed ID: 22829710
[TBL] [Abstract][Full Text] [Related]
35. Detection of Bone Metastases by
Tian R; Xie Q; Yu F; Du C; Yao X; Zang S; Zhang C; Zhang P; Shao G; Yang Z; Wang F; Yu J
Contrast Media Mol Imaging; 2022; 2022():1750132. PubMed ID: 36447752
[TBL] [Abstract][Full Text] [Related]
36. Use of molecular targeted agents for the diagnosis, staging and therapy of neuroendocrine malignancy.
Hicks RJ
Cancer Imaging; 2010 Oct; 10 Spec no A(1A):S83-91. PubMed ID: 20880795
[TBL] [Abstract][Full Text] [Related]
37. Long-term outcome of "Sandwich" chemo-PRRT: a novel treatment strategy for metastatic neuroendocrine tumors with both FDG- and SSTR-avid aggressive disease.
Parghane RV; Ostwal V; Ramaswamy A; Bhandare M; Chaudhari V; Talole S; Shrikhande SV; Basu S
Eur J Nucl Med Mol Imaging; 2021 Mar; 48(3):913-923. PubMed ID: 32876706
[TBL] [Abstract][Full Text] [Related]
38. Unmet Needs in High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms (WHO G3).
Sorbye H; Baudin E; Borbath I; Caplin M; Chen J; Cwikla JB; Frilling A; Grossman A; Kaltsas G; Scarpa A; Welin S; Garcia-Carbonero R;
Neuroendocrinology; 2019; 108(1):54-62. PubMed ID: 30153658
[TBL] [Abstract][Full Text] [Related]
39. [Clinicopathologic characteristics and prognosis of rectal neuroendocrine neoplasms].
Liu T; Liu P; Wu T; Pan Y; Chen G; Wang P; Jiang Y; Wu Y; Wang X
Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Sep; 20(9):1015-1019. PubMed ID: 28900992
[TBL] [Abstract][Full Text] [Related]
40. Circulating hsa-miR-5096 predicts
Bocchini M; Tazzari M; Ravaioli S; Piccinini F; Foca F; Tebaldi M; Nicolini F; Grassi I; Severi S; Calogero RA; Arigoni M; Schrader J; Mazza M; Paganelli G
Front Oncol; 2023; 13():1136331. PubMed ID: 37287922
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
